vadimezan has been researched along with 1,3-dihydroxy-xanthone in 2 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (1,3-dihydroxy-xanthone) | Trials (1,3-dihydroxy-xanthone) | Recent Studies (post-2010) (1,3-dihydroxy-xanthone) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 15 | 0 | 11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Jiang, Z; Liu, J; Liu, Z; Wang, H; Zhang, C; Zhang, J | 1 |
| Chen, H; Jiang, Z; Liu, J; Liu, Z; Wang, H; Zhang, C; Zhang, J; Zhang, L | 1 |
2 other study(ies) available for vadimezan and 1,3-dihydroxy-xanthone
| Article | Year |
|---|---|
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53; Xanthones | 2017 |
Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
Topics: Antineoplastic Agents; Apoptosis; Hep G2 Cells; Humans; Liver Neoplasms; Nitrates; Nitric Oxide Donors; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Structure-Activity Relationship; Tumor Suppressor Protein p53; Xanthones | 2018 |